Aadi bioscience announces poster presentations at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

Two new real-world next-generation sequencing studies reinforce prevalence of tsc1/2 mutations in up to 2% of all tumors, a significant addressable cancer population precision1 tumor-agnostic trial testing nab-sirolimus for patients with tsc 1/2 mutations on track for interim analysis on 40 patients before the end of 2023 evaluation of nab-sirolimus in preclinical combination with pi3k and akt inhibitors indicate enhanced antitumor effects in pik3ca-mutated breast cancer los angeles , oct. 12, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor pathway alterations, today announced details of four poster presentations at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics, taking place october 11-15, 2023, in boston, ma.  abstracts and poster presentation details are below: title: "inactivating tsc1 and tsc2 alterations, co-mutations, and genomic instability in advanced cancers: analysis of a real-world (rw) patient population using the foundation medicine genomic database" poster number: c019session title: poster session cdate/time: saturday, october 14, 2023, 12:30 pm-4:00 pm edt authors: david j.
AADI Ratings Summary
AADI Quant Ranking